logo
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

IRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2025 and provided a corporate strategic update.
First Quarter 2025 and Subsequent Highlights
On July 8, 2024, ReShape Lifesciences Inc. entered into a definitive merger agreement with Vyome, under which ReShape and Vyome will combine in an all-stock transaction. At the closing of the merger, ReShape will be renamed Vyome Holdings, Inc. and expects to trade under the Nasdaq ticker symbol 'HIND,' representing the company's alignment with the U.S.-India relationship. The board of directors of the combined company will be comprised of six directors designated by Vyome and one director designated by ReShape, and executive management of the combined company will consist of Vyome's executive officers.
Simultaneously with the execution of the merger agreement, ReShape entered into an asset purchase agreement with Biorad, which was amended on April 25, 2025, which is party to a previously disclosed exclusive license agreement with ReShape for ReShape's Obalon® Gastric Balloon System. Pursuant to the asset purchase agreement, ReShape will sell substantially all of its assets to Biorad (or an affiliate thereof), including ReShape's Lap-Band® System, Obalon® Gastric Balloon System and the Diabetes Bloc-Stim Neuromodulation™ (DBSN™) System (but excluding cash), and Biorad will assume substantially all of ReShape's liabilities. The cash purchase price under the asset purchase agreement will count toward ReShape's net cash for purposes of determining the post-merger ownership allocation between ReShape and Vyome stockholders under the merger agreement.
'The first quarter of 2025 and the months that followed have marked a period of strong momentum for ReShape, both operationally and strategically,' stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences®. 'We continued to expand access to our portfolio of physician-led, minimally invasive weight-loss solutions, highlighted by a new distribution agreement with Liaison Medical to launch our enhanced Lap-Band® 2.0 FLEX to the Canadian market. This partnership, following our Health Canada approval in late 2024, is a significant milestone in delivering effective, less-invasive alternatives to bariatric surgery to broader global patient base. We also expanded our product portfolio through an exclusive U.S. distribution agreement for Motion Informatics' next-generation neuromuscular rehabilitation devices, further broadening our portfolio of innovative medical devices.
'At the same time, we strengthened our leadership in diabetes innovation by presenting promising pre-clinical data on our Diabetes Neuromodulation device at the 12th Annual Minnesota Neuromodulation Symposium, in a featured poster presentation, showcasing the potential of our proprietary vagus neuromodulation technology platform. Further strengthening our position, the Diabetes Neuromodulation system received significant intellectual property protection, including multiple Notices of Allowance from the USPTO and a pivotal international patent from the Israel Patent Office. These patents extend our intellectual property coverage through at least 2039, underscoring our leadership in addressing both Type 1 and Type 2 diabetes through neuromodulation and its close association with obesity. We also received a Notice of Allowance for our intragastric device patent, which covers a next-generation, self-deflating, swallowable balloon system—an important addition to our metabolic health platform. As our patent portfolio grows, we remain committed to protecting our position and, when appropriate, will pursue strategic, non-dilutive funding to support this objective.'
Mr. Hickey concluded, 'The successful completion of our $6.0 million public offering in February strengthens our financial foundation as we continue to execute on our growth initiatives. Finally, we are making continued progress toward finalizing our merger with Vyome and the asset sale to Biorad Medisys. The S-4 was recently declared effective and we are working to set the record date in the near future. Our Board unanimously supports this transformative transaction, which we believe will unlock long-term value for shareholders and drive accelerated growth for the newly combined company.'
First Quarter Ended March 31, 2025, Financial and Operating Results
Revenue $1.1 million for the three months ended March 31, 2025, which represents a contraction of 42.7%, or $0.8 million compared to the same period in 2024. This primarily resulted from a decrease in sales volume primarily due to GLP-1 pharmaceutical weight-loss alternatives as well as a temporary pause in DTC marketing programs.
Gross Profit for the three months ended March 31, 2025 and 2024, was $0.7 million, and $1.2 million, respectively. Gross profit as a percentage of total revenue for the three months ended March 31, 2025, was 61.2% compared to 59.9% for the same period in 2024. The increase in gross profit percentage is due to the reduction in overhead related costs, primarily payroll.
Sales and Marketing Expenses for the three months ended March 31, 2025, decreased by $0.5 million, or 48.1%, to $0.5 million, compared to $1.0 million for the same period in 2024. The decrease is primarily due to a decrease in advertising and marketing expenses, including consulting and professional marketing services.
General and Administrative Expenses for the three months ended March 31, 2025, decreased by approximately $0.3 million, or 13.1%, to $1.6 million, compared to $1.9 million for the same period in 2024. The decrease is primarily due to a $0.4 million reduction in general legal, audit, and other professional fees, as the Company reduced its reliance on consultants and professional services to conserve cash.
Research and Development Expenses for the three months ended March 31, 2025, decreased by $0.1 million, or 24.8% to $0.4 million, compared to approximately $0.5 million for the same period in the prior year.
Transaction Costs for the three months ended March 31, 2025, were $0.4 million. These expenses primarily consisted of legal and audit-related fees incurred in connection with the Company's pending merger and asset sale.
Gain on changes in fair value of liability warrants for the three months ended March 31, 2025 of $3.7 million is related to the change in fair value of liability-classified warrants issued in connection with the Company's February 2025 public offering. The gain recognized in the quarter reflects the decrease in the fair value of the warrants between the issuance date and March 31, 2025.
Cash and Cash Equivalents as of March 31, 2025 were $2.6 million, including restricted cash.
About ReShape Lifesciences®
ReShape Lifesciences® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational vagal neuromodulation system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
Non-GAAP Disclosures
In addition to the financial information prepared in conformity with GAAP, we provide certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results.
Management believes that the presentation of this non-GAAP financial information provides investors with greater transparency and facilitates comparison of operating results across a broad spectrum of companies with varying capital structures, compensation strategies, and amortization methods, which provides a more complete understanding of our financial performance, competitive position, and prospects for the future. However, the non-GAAP financial measures presented in this release have certain limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the company may be different from similarly named non-GAAP financial measures used by other companies.
Adjusted EBITDA
Management uses Adjusted EBITDA in its evaluation of the company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, stock-based compensation, and other one-time costs. Management uses Adjusted EBITDA in its evaluation of the company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the company may be different from similarly named non-GAAP financial measures used by other companies.
Additional Information
In connection with the proposed Merger and Asset Sale, ReShape plans to file with the Securities and Exchange Commission (the 'SEC') and mail or otherwise provide to its stockholders a joint proxy statement/prospectus and other relevant documents in connection with the proposed Merger and Asset Sale. Before making a voting decision, ReShape's stockholders are urged to read the joint proxy statement/prospectus and any other documents filed by ReShape with the SEC in connection with the proposed Merger and Asset Sale or incorporated by reference therein carefully and in their entirety when they become available because they will contain important information about ReShape, Vyome and the proposed transactions. Investors and stockholders may obtain a free copy of these materials (when they are available) and other documents filed by ReShape with the SEC at the SEC's website at www.sec.gov, at ReShape's website at www.reshapelifesciences.com, or by sending a written request to ReShape at 18 Technology Drive, Suite 110, Irvine, California 92618, Attention: Corporate Secretary.
Participants in the Solicitation
This document does not constitute a solicitation of proxy, an offer to purchase or a solicitation of an offer to sell any securities of ReShape and its directors, executive officers and certain other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in connection with the proposed Merger and Asset Sale. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of ReShape's stockholders in connection with the proposed Merger and Asset Sale will be set forth in joint proxy statement/prospectus if and when it is filed with the SEC by ReShape and Vyome. Security holders may obtain information regarding the names, affiliations and interests of ReShape's directors and officers in ReShape's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on April 4, 2025. To the extent the holdings of ReShape securities by ReShape's directors and executive officers have changed since the amounts set forth in ReShape's proxy statement for its most recent annual meeting of stockholders, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding these individuals and any direct or indirect interests they may have in the proposed Merger and Asset Sale will be set forth in the joint proxy statement/prospectus when and if it is filed with the SEC in connection with the proposed Merger and Asset Sale, at ReShape's website at www.reshapelifesciences.com.
Forward-Looking Statements
Certain statements contained in this filing may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Merger and Asset Sale and the ability to consummate the Merger and Asset Sale. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'believes,' 'plans,' 'anticipates,' 'projects,' 'estimates,' 'expects,' 'intends,' 'strategy,' 'future,' 'opportunity,' 'may,' 'will,' 'should,' 'could,' 'potential,' or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and ReShape undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (1) ReShape may be unable to obtain stockholder approval as required for the proposed Merger and Asset Sale; (2) conditions to the closing of the Merger or Asset Sale may not be satisfied; (3) the Merger and Asset Sale may involve unexpected costs, liabilities or delays; (4) ReShape's business may suffer as a result of uncertainty surrounding the Merger and Asset Sale; (5) the outcome of any legal proceedings related to the Merger or Asset Sale; (6) ReShape may be adversely affected by other economic, business, and/or competitive factors; (7) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement or Asset Purchase Agreement; (8) the effect of the announcement of the Merger and Asset Purchase Agreement on the ability of ReShape to retain key personnel and maintain relationships with customers, suppliers and others with whom ReShape does business, or on ReShape's operating results and business generally; and (9) other risks to consummation of the Merger and Asset Sale, including the risk that the Merger and Asset Sale will not be consummated within the expected time period or at all. Additional factors that may affect the future results of ReShape are set forth in its filings with the SEC, including ReShape's most recently filed Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC's website at www.sec.gov, specifically under the heading 'Risk Factors.' The risks and uncertainties described above and in ReShape's most recent Annual Report on Form 10-K are not exclusive and further information concerning ReShape and its business, including factors that potentially could materially affect its business, financial condition or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Readers should also carefully review the risk factors described in other documents that ReShape files from time to time with the SEC. The forward-looking statements in these materials speak only as of the date of these materials. Except as required by law, ReShape assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
CONTACTS:
ReShape Lifesciences Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
[email protected]
Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
[email protected]
The following table contains a reconciliation of GAAP net income (loss) to Adjusted EBITDA attributable to common stockholders for the three months ended March 31, 2025 and 2024 (in thousands):

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Haymes Hotel Launches Sustainable Modular Hotel Suites
Haymes Hotel Launches Sustainable Modular Hotel Suites

Yahoo

time18 minutes ago

  • Yahoo

Haymes Hotel Launches Sustainable Modular Hotel Suites

LOS ANGELES, CA / / June 11, 2025 / Haymes Hotel, a forward-thinking hospitality company, announces the debut of its new line of prefabricated modular hotel suites. Designed to deliver "barefoot luxury," these turnkey suites merge architectural sophistication with environmental responsibility. A New Standard in Modular HospitalityHaymes Hotel introduces a compelling alternative to conventional lodging by offering elevated modular suites built for immersive, nature-connected experiences. Rather than following short-term trends, the brand focuses on long-term value and meaningful guest experiences. Distinct from glamping or tiny homes, each suite is fully equipped, delivering the comfort and quality of traditional hospitality while maintaining a seamless connection to the natural environment. Engineered for Local Compliance and CustomizationWhere many prefabricated developers face regulatory friction and generic output, Haymes Hotel builds every suite to local code from the outset. This site-specific compliance model accelerates approvals and mitigates costly delays. Each unit is also highly customizable. Clients can select from a curated palette of finishes and materials to ensure the suite harmonizes with its landscape. This approach balances efficiency with individuality without additional cost. Built Inside the Nation's Most Advanced Modular FacilityAll construction takes place inside a 200,000-square-foot MegaFactory in Patterson, California. The controlled environment includes dedicated work pods that eliminate weather disruptions and improve build consistency. Suites can be completed in as little as 45 days. The MegaFactory itself is powered by renewable energy, including FreeVolt PV Graf™ solar panels and Tesla's Megapack storage system. To date, over 37,000 pounds of embodied carbon have been eliminated through strategic material selection, including the avoidance of steel, copper, and vinyl. Materials are evaluated not only for performance and aesthetics but also for sustainability. For example, Haymes Hotel uses hemp fiber batt insulation made of 90% natural fiber. It contains no VOCs or toxins, delivers superior performance, and is safe for installers and guests alike. Modern Ownership Meets Direct-to-Guest TechnologyHaymes Hotel is also reimagining how rooms are marketed and managed. Guests book directly through bypassing third-party fees common to platforms like Airbnb. For owners, the company is developing proprietary software that streamlines bookings, maintenance, and performance tracking, allowing individuals to own income-producing hotel real estate with minimal overhead. About Haymes HotelHaymes Hotel designs and manufactures sustainable, prefabricated modular hotel suites for short-term rental in remote and scenic locations. Each unit is crafted to blend into its environment while offering a premium guest experience and maximizing operational efficiency. Full Name: Haymes HotelEmail Address: haymesclayton@ Angeles, CA SOURCE: Haymes Hotel View the original press release on ACCESS Newswire

S&P 500 ends lower; traders focus on Middle East tension
S&P 500 ends lower; traders focus on Middle East tension

Yahoo

time19 minutes ago

  • Yahoo

S&P 500 ends lower; traders focus on Middle East tension

STORY: U.S. stocks ended lower on Wednesday, with the Dow unchanged, the S&P 500 slipping a quarter of one percent, and the Nasdaq losing half of one percent. Wall Street erased modest gains as tensions flared in the Middle East. Sources said the U.S. was preparing a partial evacuation of its embassy in Iraq, after a senior Iranian official said Tehran will strike U.S. bases in the region if nuclear negotiations fail and if conflict arises with the United States. Investors also awaited more details on trade talks between the U.S. and China after President Donald Trump said a deal was (quote) "done," with Beijing to supply magnets and rare earth minerals. But amid the trade developments and geopolitical tensions, BMO Chief Market Strategist Carol Schleif says the stock market continues to show resilience. 'It's clearly a market that wants to look through the short term, whether it's exhausted or not, but it wants to look through short term noise and and stick with the long term fundamentals. And the fact is is the fundamentals keep coming through solidly. You know people thought we'd see more inflation out of today's CPI report and it's not being passed on. I think companies are either- They either stocked up, they're figuring out how to absorb some of it or and or they understand that consumers are just the consumers, have had it with inflation. And so, there's a big risk to passing it on.' The latest data on consumer prices showed they increased only marginally in May, while economists expect inflation to accelerate in the coming months due to the Trump administration's import tariffs. Stocks on the move Wednesday included GameStop which fell more than 5% after the video game retailer reported a decline in first-quarter revenue. And shares of Starbucks added more than 4% after its CEO told the Financial Times that it received 'a lot of interest' for its China business. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Moxie and Revision Skincare® Announce Strategic Partnership to Empower High-Growth Medspas
Moxie and Revision Skincare® Announce Strategic Partnership to Empower High-Growth Medspas

Yahoo

time34 minutes ago

  • Yahoo

Moxie and Revision Skincare® Announce Strategic Partnership to Empower High-Growth Medspas

Streamlined Ordering and Exclusive Education Now Available to Moxie-Supported Practices BROOKLYN, N.Y., June 11, 2025 /PRNewswire/ -- Moxie, the growth engine supporting over 400 aesthetic practices nationwide, today announced a strategic partnership with Revision Skincare®, the gold standard in science-backed, clinically proven skincare. This partnership brings Moxie-supported practices direct access to Revision's line of medical grade skincare, streamlined ordering, and elevated educational resources—all designed to drive profitability, operational efficiency, and exceptional client outcomes. "Independent medspas are the heartbeat of our specialty," said Kamau Massey, CEO of Moxie. "By partnering with Revision Skincare, we're expanding the ways in which we give our practices access to elite-tier products and business tools. It's about helping them compete—and win—at the highest level." This collaboration reflects a shared vision: empowering aesthetic entrepreneurs with the kind of brand alignment, service experience, and margin-boosting resources typically reserved for major enterprise clinics. "Our mission has always been to support skincare professionals with advanced innovation and education," said Joe Blahnik, Chief Sales Officer Revision Skincare®. "Moxie's commitment to the success of aesthetic practices mirrors our own—and together, we're making it easier than ever for providers to deliver exceptional results." This partnership is part of Moxie's ongoing commitment to building a best-in-class ecosystem for medspa success—uniting trusted brands that help independent practices grow, differentiate, and deliver exceptional patient experiences. About Moxie Moxie is the aesthetic practice growth and operating engine, helping medspa entrepreneurs reach multimillion dollar growth—with marketing, compliance, coaching, software, and VIP pricing, all in one place. From launch to scale, Moxie powers ambitious injectors and aesthetic entrepreneurs with the infrastructure, strategy, and partnerships they need to win in a competitive industry. About Revision Skincare® Revision Skincare® delivers high-performing, clinically validated skincare formulations rooted in rigorous research and testing. Trusted by professionals in over thirty countries across the globe, their award-winning products are designed to deliver real results—without compromising long-term skin health. Brandi EppolitoHead of MarketingMoxiebrandi@ This release was issued through WebWire®. For more information, visit View original content: SOURCE Moxie Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store